Their results indicated an annual 1.5–2.6% decrease in the incidence rate of HR negative, but with both HER2 positive and negative, breast cancer among NHW, NHB, Hispanic, AIAN and API during the study period (12). This evidence concerns the gene ERBB2 and breast carcinoma.